A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes

Cancer Genetics

Volumn 204, Issue 4, 2011, Pages 187-194

  MacKinnon, Ruth N ^a   Kannourakis, George ^b   Wall, Meaghan ^a   Campbell, Lynda J ^a,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b Ballarat Oncology and Haematology Services   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chromosome 5; Common deleted region; Deletion; EGR1; Myelodysplastic syndromes

Indexed keywords

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BLAST CELL; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER GROWTH; CASE REPORT; CHROMOSOME 5Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION 5; CHROMOSOME G BAND; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE ASSOCIATION; DYSERYTHROPOIESIS; EGR1 GENE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPING; MALE; PANCYTOPENIA; PRIORITY JOURNAL; REFRACTORY ANEMIA; CHROMOSOME 5; CHROMOSOME DELETION; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; MYELODYSPLASTIC SYNDROME;

AGED; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; COMPARATIVE GENOMIC HYBRIDIZATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 79960069645     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.02.001     Document Type: Article

References (35)

1. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
2. Haase D., Germing U., Schanz J., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 10:4385-4395.
3. Jaju R.J., Boultwood J., Oliver F.J., et al. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. Genes Chromosomes Cancer 1998, 22:251-256.
4. Boultwood J., Lewis S., Wainscoat J.S. The 5q- syndrome. Blood 1994, 84:3253-3260.
5. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon. 4th ed. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
6. Ebert B.L., Pretz J., Bosco J., et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008, 451:335-339.
7. Seong D.C., Kantarjian H.M., Ro J.Y., et al. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995, 86:2343-2349.
8. Webber L.M., Garson O.M. Fluorodeoxyuridine synchronization of bone marrow cultures. Cancer Genet Cytogenet 1983, 8:123-132.
9. Moorhead P.S., Nowell P.C., Mellman W.J., et al. Chromosome preparations of leukocytes cultured from human peripheral blood. Exp Cell Res 1960, 20:613-616.
10. Seabright M. The use of proteolytic enzymes for the mapping of structural rearrangements in the chromosomes of man. Chromosoma 1972, 36:204-210.
11. ISCN (2009): an international system for human cytogenetic nomenclature 2009, S. Karger, Basel. L.G. Shaffer, M.L. Slovak, L.J. Campbell (Eds.).
12. Evers C., Beier M., Poelitz A., et al. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Genes Chromosomes Cancer 2007, 46:1119-1128.
13. Hubbard T.J., Aken B.L., Ayling S., et al. Ensembl 2009. Nucleic Acids Res 2009, 37(Database issue):D690-D697.
14. MacKinnon R.N., Patsouris C., Chudoba I., et al. A FISH comparison of variant derivatives of the recurrent dic(17;20) of myelodysplastic syndromes and acute myeloid leukemia: obligatory retention of genes on 17p and 20q may explain the formation of dicentric chromosomes. Genes Chromosomes Cancer 2007, 46:27-36.
15. Kreatech Instruction manual for Poseidon diagnostic probes 2007, Kreatech Diagnostics, Amsterdam.
16. Mohamedali A., Gaken J., Twine N.A., et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007, 110:3365-3373.
17. Lai F., Godley L.A., Joslin J., et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics 2001, 71:235-245.
18. Horrigan S.K., Arbieva Z.H., Xie H.Y., et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood 2000, 95:2372-2377.
19. Zhao N., Stoffel A., Wang P.W., et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A 1997, 94:6948-6953.
20. Fairman J., Chumakov I., Chinault A.C., et al. Physical mapping of the minimal region of loss in 5q- chromosome. Proc Natl Acad Sci U S A 1995, 92:7406-7410.
21. Fairman J., Wang R.Y., Liang H., et al. Translocations and deletions of 5q13.1 in myelodysplasia and acute myelogenous leukemia: evidence for a novel critical locus. Blood 1996, 88:2259-2266.
22. Liang J.C., Ning Y., Wang R.Y., et al. Spectral karyotypic study of the HL-60 cell line: detection of complex rearrangements involving chromosomes 5, 7, and 16 and delineation of critical region of deletion on 5q31.1. Cancer Genet Cytogenet 1999, 113:105-109.
23. Guenet L., Toutain B., Guilleret I., et al. Human release factor eRF1: structural organisation of the unique functional gene on chromosome 5 and of the three processed pseudogenes. FEBS Lett 1999, 454:131-136.
24. Joslin J.M., Fernald A.A., Tennant T.R., et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007, 110:719-726.
25. Le Beau M.M., Espinosa R., Neuman W.L., et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A 1993, 90:5484-5488.
26. Krishnaraju K., Nguyen H.Q., Liebermann D.A., et al. The zinc finger transcription factor Egr-1 potentiates macrophage differentiation of hematopoietic cells. Mol Cell Biol 1995, 15:5499-5507.
27. Nguyen H.Q., Hoffman-Liebermann B., Liebermann D.A. The zinc finger transcription factor Egr-1 is essential for and restricts differentiation along the macrophage lineage. Cell 1993, 72:197-209.
28. Gibbs J.D., Liebermann D.A., Hoffman B. Egr-1 abrogates the E2F-1 block in terminal myeloid differentiation and suppresses leukemia. Oncogene 2008, 27:98-106.
29. Hu Z., Gomes I., Horrigan S.K., et al. A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31. Oncogene 2001, 20:6946-6954.
30. Graubert T.A., Payton M.A., Shao J., et al. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One 2009, 4:e4583.
31. Saito H., Kubota M., Roberts R.W., et al. RTP family members induce functional expression of mammalian odorant receptors. Cell 2004, 119:679-691.
32. Olszewski S., Deeney J.T., Schuppin G.T., et al. Rab3A effector domain peptides induce insulin exocytosis via a specific interaction with a cytosolic protein doublet. J Biol Chem 1994, 269:27987-27991.
33. Dubourg C., Toutain B., Helias C., et al. Evaluation of ETF1/eRF1, mapping to 5q31, as a candidate myeloid tumor suppressor gene. Cancer Genet Cytogenet 2002, 134:33-37.
34. Guenet L., Henry C., Toutain B., et al. Eukaryotic translation termination factor gene (ETF1/eRF1) maps at D5S500 in a commonly deleted region of chromosome 5q31 in malignant myeloid diseases. Cytogenet Cell Genet 2000, 88:82-86.
35. Zhang F.F., Murata-Collins J.L., Gaytan P., et al. Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia. Genes Chromosomes Cancer 2000, 28:318-328.